December 5, 2017 / 6:23 AM / 13 days ago

BRIEF-Novo' Xultophy reported as better option than basal-bolus insulin therapy to manage type 2 diabetes

Dec 5 (Reuters) - NOVO NORDISK A/S:

* XULTOPHY REPORTED A BETTER OPTION THAN BASAL-BOLUS INSULIN THERAPY TO MANAGE TYPE 2 DIABETES BY PARTICIPANTS IN THE DUAL VII CLINICAL TRIAL

* THIS WAS REPORTED BY PEOPLE WITH TYPE 2 DIABETES WHOSE BLOOD SUGAR WAS NOT CONTROLLED ON INSULIN GLARGINE U100 WITH METFORMIN, AND WHO COMPLETED QUALITY-OF-LIFE QUESTIONNAIRES AS PART OF THE DUAL VII CLINICAL TRIAL

* MORE PEOPLE PREFERRED TO STAY ON XULTOPHY COMPARED WITH BASAL-BOLUS THERAPY (84.5 PCT VERSUS 68.1 PCT)

* RESULTS WERE PRESENTED AT THE 2017 INTERNATIONAL DIABETES FEDERATION CONGRESS IN ABU DHABI, UAE. SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE: (Copenhagen newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below